Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases
Summary
Predicta Biosciences raised $23.4 million in Series A funding to expand its diagnostic and analytics platform for blood cancers and autoimmune diseases. The round was led by Engine Ventures with participation from several life sciences investors and strategic backers. The company also named Brian McKernan as its new CEO. Predicta will use the capital to scale GenoPredicta and advance precision diagnostics and therapeutics for conditions such as multiple myeloma.
Funding
Amount
$23.4M
Total raised
Date
October 1, 2025
Announcement date
Investors
American Cancer Society, Dana Farber Cancer Institute, Illumina
Lead investors
Company
predictabiosciences.com
Funded company
Classifications
industries
No industries detected
applications
AI & Machine learning
AskAI Classifications
Labels
No AI classifications detected